Online Agenda
* All times shown in EST
8:30am | Virtual Coffee Morning
9:15am | Chair’s Opening Remarks
Engineering Exosomes for More Efficient Therapies
9:25 am Selecting Preferred Cells for Engineering Exosomes
Synopsis
- Different cells produce exosomes with different microRNA signatures
- Can the microRNA profile inform clinical use?
- Enhancing angiogenic potential by microRNA knockdown
9:50 am Engineering Extracellular Vesicles for the Delivery of Gene Editing Tools
Synopsis
- Strategies for loading of therapeutic cargo into EVs, and characterization of engineered EV at the single-vesicle and single-molecule level
- Application of EVs loaded with CRISPR/Cas9 to promote gene editing in in vitro models
- Safety and in vivo biodistribution of engineered EVs
10:15 am Live Presenter Q&A
Synopsis
- Ask the speakers your most burning questions!
10:30 am Improvements in Fluorescent Nanoparticle Tracking Analysis: Reliable Characterization of Extracellular Vesicles
Synopsis
• Nanoparticle Tracking Analysis (NTA) has emerged to a vital and fast
characterization technology for exosomes, microvesicles or viruses
• In combination with fluorescence detection (F-NTA), NTA enables the
user to perform biomarker detection on the single particle level, thus
enhancing real EV concentration measurements
• Here we report the multi-fluorescence detection of four independent
biomarkers (CD63, CD81, CD9 and CD41) in one NTA sample for the first
time
11:00am | Virtual Speed Networking
11:45 am PANEL DISCUSSION: Comparing Engineered & Naturally Derived Exosomes for Therapeutic Benefit
Synopsis
- Is engineering exosomes even necessary? Comparing across disease indications
- Strategies to test the capacity of both
- What are the advantages of engineering exosomes as therapeutics and as drug delivery vehicles?
- Linking engineering to the successful loading of cargo
- Regulatory considerations of engineering exosomes at scale
Determining the Mechanisms of Action of Exosome-Based Therapeutics
12:30 pm Mechanistic Insights into Extracellular Vesicle-Mediated RNA Delivery
Synopsis
- A novel CRISPR-Cas9-based reporter system allows study of EV-mediated functional RNA transfer on a single cell level
- Regulatory mechanisms in EV-mediated RNA transfer are being explored
- EVs outperform synthetic carriers in terms of delivery efficiency
12:55 pm Neural Exosome for Delivery to Central Nervous System
Synopsis
- Nucleic acid payload delivery and efficacy is enhanced in extracellular vesicles when combinatory approaches are used
- Neural exosome from non-transformed neural stem cells have specific anti-inflammatory mechanisms of action
- Neural exosomes are being mined for blood brain barrier and neural specific targets
1:20 pm Live Presenter Q&A
Synopsis
- Ask the speakers your most burning questions!
1:35pm | Networking Lunch
2:20 pm Hypothalamic Neural Stem Cell-Based EV Therapeutics
Synopsis
- Hypothalamic neural stem cell (htNSC)-secreted EVs: roles for the brain and whole body homeostasis;
- EV from htNSC subtypes: peptide profile and EV characterization
- Secretome-based htNSC EV therapeutics for aging and diabetes
2:45 pm Cell and Tissue Reprogramming Using Extracellular Vesicles: Applications in Regenerative Medicine
Synopsis
-
- Quantitative mass spectrometry in defining and understanding extracellular vesicles
- Targeting extracellular vesicles for delivery – understanding the surfaceome
- Phosphoproteomic characterization of the EV-mediated signalling network
- Regenerative approach for cell (free) therapy – strategies for reprogramming cell and tissue environment
3:05 pm Understanding the Roles of Extracellular Vesicles in Rheumatoid Arthritis
Synopsis
- Details to be revealed
3:35 pm Live Presenter Q&A
Synopsis
- Ask the speakers your most burning questions!
3:50pm | Afternoon Networking Break
Driving Forward Preclinical Outcomes to Advance into the Clinic
4:30 pm Exosomes Displaying CD24 (EXO-CD24) – A Breakthrough Platform for Amelioration Of Immune Hyper-Activation
Synopsis
- Development of a new anti inflammatory drug EXO CD24, a combination of immune-checkpoint-protein CD24 with exosomes-based delivery
- EXO-CD24 was produced by over-expression of CD24 in cells, followed by purification of exosomes from the growth medium
- EXO-HSA were examined in mouse inflammatory disease models
- It is suggested that EXO-CD24 may serve as a novel drug platform for pulmonary and systemic diseases with an underlying immune hyperactivation pathology
4:55 pm Preclinical Research of Aegle’s Isolated EVs Promotes Cell Proliferation & Protein Production
Synopsis
• EVs carry the signals of cells and have the potential to be used as a
therapeutic
• EVs induce cell proliferation and angiogenesis in preclinical research
• EVs induce protein production in diseased cells
5:20 pm Bridging the Gap Between Chemotherapy and Immunotherapy; EV Therapeutics Show Promise in Oncology Preclinical Studies
Synopsis
- Six years of mechanistic and pre-clinical studies will be presented for a novel, first-in-class immunomodulator.
- Learn how the immune response prevents checkpoint inhibitors from being effective in solid tumors
- Understand how modified tumor cell -derived extracellular vesicles overcome T-cell exhaustion and synergize with checkpoint inhibitors to potentially allow patient to transition from chemotherapy to immunotherapy
5:45 pm Live Presenter Q&A
Synopsis
- Ask the speakers your most burning questions!